Want to see DCTH full AI Analyst Report?
DCTH Stock Chart & Stats
$16.39
-$0.28(-2.29%)
At close: 4:00 PM EDT
$16.39
-$0.28(-2.29%)
Day’s Range― - ―
52-Week Range$8.12 - $17.42
Previous Close$12.03
Volume439.54K
Average Volume (3M)335.70K
Market Cap
$512.15M
Enterprise Value$407.16M
Total Cash (Recent Filing)$95.90M
Total Debt (Recent Filing)$2.46M
Price to Earnings (P/E)1336.4
Beta1.71
Next Earnings
Nov 10, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.01
Shares Outstanding34,698,795
10 Day Avg. Volume275,345
30 Day Avg. Volume335,698
Financial Highlights & Ratios
PEG Ratio-0.72
Price to Book (P/B)3.25
Price to Sales (P/S)4.24
P/FCF Ratio17.25
Enterprise Value/Market Cap0.79
Enterprise Value/Revenue4.27
Enterprise Value/Gross Profit4.90
Enterprise Value/Ebitda226.96
Forecast
1Y Price Target
$24.50Price Target Upside49.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.18
Revenue Forecast (FY)$106.44M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthThe sustained revenue scale-up indicates expanding commercialization of Delcath’s liver-directed therapy platform. Continued growth can broaden the treated-patient base, improve utilization across activated centers, and provide operating leverage if administrative and commercial costs grow more slowly than sales.
High Gross MarginsGross margins in the mid-to-high 80% range provide substantial contribution potential from each additional procedure and product sale. This economics profile supports reinvestment in commercialization and clinical adoption, while creating a foundation for stronger earnings if revenue growth becomes more efficiently scaled.
Cash Generation And Low LeveragePositive operating and free cash flow, combined with very low leverage, gives Delcath greater flexibility to fund commercialization and investment without relying heavily on debt. This financial capacity can help the company pursue growth while providing a cushion against execution variability.
Bears Say
Fragile ProfitabilityNear-breakeven net income and slightly negative TTM operating profit show that strong gross margins have not yet translated into durable operating earnings. Results may remain sensitive to commercial spending, expense levels, and product mix until revenue growth consistently produces operating leverage.
Business ConcentrationHeavy dependence on one principal product and the U.S. market concentrates Delcath’s growth and execution exposure. Any slower adoption, reimbursement pressure, or market-specific setback affecting Hepzato could have an outsized effect on revenue, cash generation, and the pace of profitability improvement.
Free Cash Flow VolatilityPositive free cash flow is encouraging, but the year-over-year decline indicates that cash conversion has not followed a consistently improving path. Continued volatility could reduce the funds available for commercialization and investment, making future expansion more dependent on operating execution.
Delcath Systems News
DCTH FAQ
What was Delcath Systems’s price range in the past 12 months?
Delcath Systems lowest stock price was $8.12 and its highest was $17.42 in the past 12 months.
What is Delcath Systems’s market cap?
Delcath Systems’s market cap is $512.15M.
When is Delcath Systems’s upcoming earnings report date?
Delcath Systems’s upcoming earnings report date is Nov 10, 2026 which is in 18 days.
How were Delcath Systems’s earnings last quarter?
Delcath Systems released its earnings results on Aug 06, 2026. The company reported $0.07 earnings per share for the quarter, beating the consensus estimate of -$0.089 by $0.159.
Is Delcath Systems overvalued?
According to Wall Street analysts Delcath Systems’s price is currently Undervalued.
Does Delcath Systems pay dividends?
Delcath Systems does not currently pay dividends.
What is Delcath Systems’s EPS estimate?
Delcath Systems’s EPS estimate is -0.09.
How many shares outstanding does Delcath Systems have?
Delcath Systems has 34,698,795 shares outstanding.
What happened to Delcath Systems’s price movement after its last earnings report?
Delcath Systems reported an EPS of $0.07 in its last earnings report, beating expectations of -$0.089. Following the earnings report the stock price went up 22.486%.
Which hedge fund is a major shareholder of Delcath Systems?
Currently, no hedge funds are holding shares in DCTH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Delcath Systems Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.50 (49.48% Upside)
$24.50 (49.48% Upside)
Blogger Sentiment
Bullish
DCTH Sentiment 100%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 185.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.3%
Last 30 Days ▼ 5.2%
Last 30 Days ▼ 5.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
42.37%
12-Months-Change
Fundamentals
Return on Equity
0.46%
Trailing 12-Months
Asset Growth
17.23%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Delcath Systems
Delcath Systems, Inc. is an interventional oncology firm operating in the United States and Europe, dedicated to developing treatments for both primary and secondary liver cancers. Its leading investigational product is the HEPZATO KIT, a unique hepatic delivery system for melphalan that targets high-dose chemotherapy specifically to the liver. This innovative approach aims to substantially reduce systemic drug exposure and mitigate associated side effects. HEPZATO's clinical evaluation is advancing through the FOCUS trial, which is designed to assess the objective response rate in individuals with metastatic uveal melanoma whose disease is primarily concentrated in the liver. Furthermore, the company offers a separate version of HEPZATO as a medical device in Europe, marketed under the CHEMOSAT Hepatic Delivery System brand (or simply CHEMOSAT). This system empowers European medical centers to manage a diverse array of liver cancer conditions. Delcath Systems, Inc. was established in 1988, with its corporate headquarters situated in New York, New York.
DCTH Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a balanced mix of positive commercial and clinical momentum (record new patient starts, robust volume growth, encouraging CHOPIN data driving adoption, solid revenue growth and strong cash balance) alongside meaningful near-term operational and financial headwinds (slower-than-expected site activations and trial enrollment, higher R&D and SG&A spend, a quarter-over-quarter decline in adjusted EBITDA and a small net loss, plus European reimbursement constraints and seasonality risks). Management remains optimistic about hitting at least $100M in revenue for 2026 and returning to positive adjusted EBITDA for the year, but several execution and enrollment risks temper the outlook.View all DCTH earnings summariesDCTH Stock 12 Month Forecast
Average Price Target
$24.50
▲(49.48% Upside)
Technical Analysis
Ownership Overview
31.45% Insiders
7.27% Mutual Funds
0.44% Other Institutional Investors
51.11% Public Companies and
Individual Investors